Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advanced BiomedADVB -3.23%12 3-1 Month Momentum % is -31.30% as of Jul. 14, 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 215 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 92.09% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-14), Advanced Biomed's 3-1 Month Momentum % is -31.30%.
The industry rank for Advanced Biomed's 3-1 Month Momentum % or its related term are showing as below:
ADVB's 3-1 Month Momentum % is ranked worse than 92.09% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -5.88
vs ADVB: -31.30
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Advanced Biomed 3-1 Month Momentum % Related Terms
ADVB vs MBAI, XWEL, NDRA: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Advanced Biomed's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Biomed (ADVB) has a 3-1 Month Momentum % of -31.30% as of Jul. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #198 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 92.1%.
Is Advanced Biomed's 3-1 Month Momentum % too high?
Advanced Biomed's current 3-1 Month Momentum % is -31.30%. Based on the distribution chart, Advanced Biomed ranks #198 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's 3-1 Month Momentum % compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #198 out of 215 companies for 3-1 Month Momentum %. This places Advanced Biomed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Advanced Biomed and its competitors. Advanced Biomed's current 3-1 Month Momentum % is -31.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current 3-1 Month Momentum % of -31.30%. The current 3-1 Month Momentum % is -31.30%. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current 3-1 Month Momentum % is -31.30% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
